EB
Therapeutic Areas
Geron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Imetelstat (Rytelo™) | Transfusion-Dependent Anemia in Lower-Risk Myelodysplastic Syndromes (MDS) | Approved |
| Imetelstat | JAK Inhibitor Relapsed/Refractory Myelofibrosis (MF) | Phase 3 |
| Imetelstat + Ruxolitinib | Frontline Myelofibrosis (MF) | Phase 1 |
| Imetelstat + Azacitidine ± Venetoclax | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1/2 |